Page 56 - Read Online

Page 14 of 18 Qin et al. Hepatoma Res 2020;6:24 I http://dx.doi.org/10.20517/2394-5079.2020.04

promote progression of hepatocellular carcinoma and resistance to sorafenib. Gastroenterology 2016;150:1646-58.e17.
12. Li ZQ, Wang HY, Zeng QL, Yan JY, Hu YS, et al. p65/miR-23a/CCL22 axis regulated regulatory T cells recruitment in hepatitis B
virus positive hepatocellular carcinoma. Cancer Med 2020;9:711-23.
13. Zhou J, Ding T, Pan W, Zhu LY, Li L, et al. Increased intratumoral regulatory T cells are related to intratumoral macrophages and poor
prognosis in hepatocellular carcinoma patients. Int J Cancer 2009;125:1640-8.
+
+
14. Sharma S, Khosla R, David P, Rastogi A, Vyas A, et al. CD4 CD25 CD127(low) regulatory T cells play predominant anti-tumor
suppressive role in hepatitis B virus-associated hepatocellular carcinoma. Front Immunol 2015;6:49.
15. Zhu Y, Yang J, Xu D, Gao XM, Zhang Z, et al. Disruption of tumour-associated macrophage trafficking by the osteopontin-induced
colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade. Gut 2019;68:1653-66.
16. Kuang DM, Peng C, Zhao Q, Wu Y, Chen MS, et al. Activated monocytes in peritumoral stroma of hepatocellular carcinoma promote
expansion of memory T helper 17 cells. Hepatology 2010;51:154-64.
17. Fu Y, Liu S, Zeng S, Shen H. From bench to bed: the tumor immune microenvironment and current immunotherapeutic strategies for
hepatocellular carcinoma. J Exp Clin Cancer Res 2019;38:396.
18. Darvishi B, Majidzadeh AK, Ghadirian R, Mosayebzadeh M, Farahmand L. Recruited bone marrow derived cells, local stromal cells
and IL-17 at the front line of resistance development to anti-VEGF targeted therapies. Life Sci 2019;217:34-40.
19. Chang CP, Su YC, Lee PH, Lei HY. Targeting NFKB by autophagy to polarize hepatoma-associated macrophage differentiation.
Autophagy 2013;9:619-21.
20. Nicolas-Avila JA, Adrover JM, Hidalgo A. Neutrophils in homeostasis, immunity, and cancer. Immunity 2017;46:15-28.
21. Andzinski L, Kasnitz N, Stahnke S, Wu CF, Gereke M, et al. Type I IFNs induce anti-tumor polarization of tumor associated
neutrophils in mice and human. Int J Cancer 2016;138:1982-93.
22. Michaeli J, Shaul ME, Mishalian I, Hovav AH, Levy L. Tumor-associated neutrophils induce apoptosis of non-activated CD8 T-cells
in a TNFalpha and NO-dependent mechanism, promoting a tumor-supportive environment. Oncoimmunology 2017;6:e1356965.
23. Margetts J, Ogle LF, Chan SL, Chan AWH, Chan KCA, et al. Neutrophils: driving progression and poor prognosis in hepatocellular
carcinoma? Br J Cancer 2018;118:248-57.
24. Mano Y, Shirabe K, Yamashita Y, Harimoto N, Tsujita E, et al. Preoperative neutrophil-to-lymphocyte ratio is a predictor of survival
after hepatectomy for hepatocellular carcinoma: a retrospective analysis. Ann Surg 2013;258:301-5.
25. Zhou SL, Zhou ZJ, Hu ZQ, Huang XW, Wang Z, et al. Tumor-associated neutrophils recruit macrophages and T-regulatory cells to
promote progression of hepatocellular carcinoma and resistance to sorafenib. Gastroenterology 2016;150:1646-58.e17.
26. Zhou SL, Yin D, Hu ZQ, Luo CB, Zhou ZJ, et al. A positive feedback loop between cancer stem-like cells and tumor-associated
neutrophils controls hepatocellular carcinoma progression. Hepatology 2019;70:1214-30.
27. Robinson MW, Harmon C, O’Farrelly C. Liver immunology and its role in inflammation and homeostasis. Cell Mol Immunol
2016;13:267-76.
28. Sundstrom P, Szeponik L, Ahlmanner F, Sundquist M, Wong JSB, et al. Tumor-infiltrating mucosal-associated invariant T (MAIT)
cells retain expression of cytotoxic effector molecules. Oncotarget 2019;10:2810-23.
29. Gajewski TF, Schreiber H, Fu YX. Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol 2013;14:1014-22.
30. Parodi M, Raggi F, Cangelosi D, Manzini C, Balsamo M, et al. Hypoxia modifies the transcriptome of human NK cells, modulates
their immunoregulatory profile, and influences NK cell subset migration. Front Immunol 2018;9:2358.
31. Sheppard S, Ferry A, Guedes J, Guerra N. The paradoxical role of NKG2D in cancer immunity. Front Immunol 2018;9:1808.
32. Chambers AM, Lupo KB, Matosevic S. Tumor microenvironment-induced immunometabolic reprogramming of natural killer cells.
Front Immunol 2018;9:2517.
33. Dengler VL, Galbraith M, Espinosa JM. Transcriptional regulation by hypoxia inducible factors. Crit Rev Biochem Mol Biol
2014;49:1-15.
34. Vujanovic L, Stahl EC, Pardee AD, Geller DA, Tsung A, et al. Tumor-derived alpha-fetoprotein directly drives human natural killer-
cell activation and subsequent cell death. Cancer Immunol Res 2017;5:493-502.
35. Sun C, Sun H, Zhang C, Tian Z. NK cell receptor imbalance and NK cell dysfunction in HBV infection and hepatocellular carcinoma.
Cell Mol Immunol 2015;12:292-302.
36. Cai L, Zhang Z, Zhou L, Wang H, Fu J, et al. Functional impairment in circulating and intrahepatic NK cells and relative mechanism
in hepatocellular carcinoma patients. Clin Immunol 2008;129:428-37.
37. Fan Y, Gao Y, Rao J, Wang K, Zhang F, et al. YAP-1 promotes tregs differentiation in hepatocellular carcinoma by enhancing TGFBR2
transcription. Cell Physiol Biochem 2017;41:1189-98.
38. Wu R, Liu C, Deng X, Chen L, Hao S, et al. Enhanced alleviation of aGVHD by TGF-beta1-modified mesenchymal stem cells in mice
through shifting MPhi into M2 phenotype and promoting the differentiation of Treg cells. J Cell Mol Med 2020;24:1684-99.
39. Gao Q, Qiu SJ, Fan J, Zhou J, Wang XY, et al. Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of
hepatocellular carcinoma after resection. J Clin Oncol2007;25:2586-93.
40. Fu J, Xu D, Liu Z, Shi M, Zhao P, et al. Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in
hepatocellular carcinoma patients. Gastroenterology 2007;132:2328-39.
41. Yang XH, Yamagiwa S, Ichida T, Matsuda Y, Sugahara S, et al. Increase of CD4 CD25 regulatory T-cells in the liver of patients with
+
+
hepatocellular carcinoma. J Hepatol 2006;45:254-62.
42. Guo CL, Yang XH, Cheng W, Xu Y, Li JB, et al. Expression of Fas/FasL in CD8 T and CD3 Foxp3 Treg cells--relationship with
+
+
+
+
apoptosis of circulating CD8 T cells in hepatocellular carcinoma patients. Asian Pac J Cancer Prev 2014;15:2613-8.
43. Huang CY, Wang H, Liao W, Han F, Li YQ, et al. Transforming growth factor beta is a poor prognostic factor and inhibits the
+
favorable prognostic value of CD8 CTL in human hepatocellular carcinoma. J Immunother 2017;40:175-86.
44. Sun Z, Ren Z, Yang K, Liu Z, Cao S, et al. A next-generation tumor-targeting IL-2 preferentially promotes tumor-infiltrating CD8(+)